Newer Study Shows Psilocybin Can Provide Relief from Depression

Psilocybin may just change the way we address mental health forever.

It may even revolutionize how major pharmaceutical giants tackle a good deal of mental health issues. After all, a recent study of 24 adults with major depression published in the journal JAMA Psychiatry found that two doses led to a large reduction in depression symptoms.

According to Alan Davis from the Johns Hopkins University School of Medicine, as quoted by New Atlas, "The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market."

"Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future 'gold-standard' placebo-controlled clinical trials," he added.

The U.S. is seeing broader support of psilocybin use, as well.

Just last week, Oregon became the first state to legalize psilocybin in a therapeutic setting. With Measure 109, the psilocybin movement is about overcoming depression, as noted by KATU 2 ABC. In addition, "An estimated 1 in every 5 adults in Oregon is coping with a mental health condition," 20 doctors and other health care workers wrote in the voters' pamphlet.

"We support Measure 109 because it provides a new treatment for many that might break through where others fall short."

With big progress being made, psilocybin could change mental health treatment for the better.

Better Plant Sciences (CSE: PLNT) (OTC: VEGGF) is Part of the Growing Psilocybin Story

Better Plant Sciences' majority owned subsidiary NeonMind Biosciences entered into a definitive agreement with Psygen Labs Inc. for the supply of psilocybin for NeonMind's planned preclinical, and clinical trials to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety.

"Psilocybin is known to activate serotonin receptors," says Dr. William Panenka, lead scientific advisor to NeonMind. "As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings."

"Psygen's mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research," says Danny Motyka, CEO of Psygen Labs Inc. "We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem."

"Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics."

For more information, visit the company's website at https://betterplantsciences.com

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and Better Plant Sciences Inc., Winning Media has been paid two thousand dollars for advertising and marketing services for Better Plant Sciences Inc. We own ZERO shares of Better Plant Sciences Inc. Please click here for full disclaimer.

Contact Information:
2818047972
ty@lifewatermedia.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67961

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Cannabis leaf in front of US and Canada flags with the words Cannabis Weekly Round-Up.

Cannabis Round-Up: US DEA Proposes Rescheduling, Canada Ignores Company Tax Concerns

April was a game-changer for the cannabis industry.

After deliberating for almost five months, the Drug Enforcement Administration moved to reschedule cannabis as lawmakers worked to combine the SAFER Banking Act with newly introduced stablecoin legislation.

Meanwhile, controversy struck as legal cannabis was seized in New Mexico, Canada's Federal Budget 2024 was released with no mention of reform to high excise tax rates, and the saga of a once high-end cannabis dispensary finally ended in bankruptcy.

Keep reading...Show less

Goodness Growth Holdings Announces Filing of Application for Summary Determination in Litigation with Verano

Filing reflects Company's belief that Verano's defense against claims of unlawful conduct is without merit –

– Legal filing represents a documentary record and corresponding damages analysis –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Court gavel in front of national flag of the USA having shadows of cannabis on wooden table.

DEA Submits Proposal to Reschedule Cannabis, Stocks Rally

The Associated Press reported Tuesday (April 30) that the US Drug Enforcement Administration (DEA) was on the cusp of rescheduling cannabis from a Schedule I substance, the same category as heroin and methamphetamines, to Schedule III.

The Department of Health and Human Services suggested cannabis be reclassified on August 29, 2023, and the DEA has been deliberating on the decision for months, urged by lawmakers to heed the recommendation.

According to the report, Attorney General Merrick Garland was scheduled to submit the proposal to the White House Office of Management and Budget on Tuesday afternoon. President Biden has been vocal about his stance on this issue and has urged the Attorney General to expedite the process, suggesting his readiness to move forward once the proposal reaches his desk.

Keep reading...Show less

Goodness Growth Provides CREAM & Fire Updates

Josh Rosen to shed Interim title and become Chief Executive Officer; Company provides other key personnel updates –

– Company receives a short-term extension of the maturity date on its credit facility –

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024

Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the market closes.

Goodness Growth management will host a conference call with the investment community that day, Tuesday, May 7, 2024 at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET.

Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×